Development Research Program
发展研究计划
基本信息
- 批准号:10415941
- 负责人:
- 金额:$ 9.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-16 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Developmental Research Program: Project Summary/Abstract
This SPORE in Melanoma Developmental Research Program (DRP) serves to identify and fund pilot projects
that take maximum advantage of new research breakthroughs and novel ideas that may eventually reduce the
incidence and morbidity or increase the survival of patients with melanoma. Progress in understanding of
melanoma biology and the role of immune response in melanoma patient outcomes has led to substantial
advances in both targeted and immunotherapies for melanoma patients, and much promise is held for
immediate future advances. Therefore, we are particularly interested in leveraging novel ideas from
investigators with a variety of expertise in this DRP, and providing seed money for testing creative hypotheses
and obtaining preliminary data for projects that are not supported by current or alternative funding sources.
High risk/high reward pilot projects are especially prioritized, and applications from women and minority or
underserved investigators are strongly encouraged. The available DRP funds include the required $50,000
annually throughout the duration of the SPORE award, as well as an annual contribution of up to $100,000
from institutional “matching funds,” for a total of $150,000 per year. Applications for SPORE DRPs are solicited
annually, with an aim to fund at least 3 one-year awards of up to $50,000 each, with the possibility of ongoing
support for a second year award of $50,000 if requested and approved based on acceptable progress.
Philanthropic funds will also be utilized if available to support high quality proposals. Projects that provide a
“pipeline” of additional value to the main SPORE projects or that support other new or concurrent melanoma
grants are welcomed.
发展研究计划:项目摘要/摘要
黑色素瘤发展研究计划(DRP)的这个孢子用于确定和资助试点项目
最大限度地利用新的研究突破和新的想法,最终可能减少
发病率和发病率或增加黑色素瘤患者的存活率。在了解
黑色素瘤生物学和免疫应答在黑色素瘤患者结局中的作用已经导致了大量的
黑色素瘤患者的靶向治疗和免疫治疗都取得了进展,
未来的进步。因此,我们特别感兴趣的是利用来自
在这个DRP中拥有各种专业知识的调查人员,并为测试创造性假设提供种子资金
以及为目前或其他资金来源不支持的项目获取初步数据。
高风险/高回报的试点项目尤其受到优先重视,妇女和少数民族或
大力鼓励服务不足的调查人员。可用的DRP资金包括所需的5万美元
在整个SPORE奖期间,每年提供一次,以及每年高达10万美元的捐款
从机构“配套资金”中拨款,每年共计15万美元。政府现正征集“孢子回收计划”的申请
每年,目的是资助至少3个一年期的奖项,每个奖项最高可达50,000美元,并有可能持续
如果根据可接受的进展提出请求并获得批准,则支持第二年的50 000美元奖励。
如果有慈善基金,也将用于支持高质量的提案。提供一个
对主要SPORE项目或支持其他新的或同时发生的黑色素瘤具有附加价值的“管道”
赠款是受欢迎的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephanie S Watowich其他文献
UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies
- DOI:
10.1182/blood-2023-187438 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Chiharu Ishikawa;Laura Barreyro;Avery Sampson;Kathleen Hueneman;Kwangmin Choi;Lyndsey C. Bolanos;Andrew Volk;Stephanie S Watowich;Kenneth Greis;Daniel T. Starczynowski - 通讯作者:
Daniel T. Starczynowski
STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions
- DOI:
10.1182/blood-2022-170250 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Bhakti Patel;Yifan Zhou;Rachel L Babcock;Feiyang Ma;Yusra B Medik;Laura M Kahn;Josue E Pineda;Elizabeth Park;Karen Clise-Dwyer;Simona Colla;Stephanie S Watowich - 通讯作者:
Stephanie S Watowich
Stephanie S Watowich的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephanie S Watowich', 18)}}的其他基金
Regulation and function of nonlymphoid organ CD103+ dendritic cells
非淋巴器官CD103树突状细胞的调节和功能
- 批准号:
10469028 - 财政年份:2021
- 资助金额:
$ 9.58万 - 项目类别:
Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity
定义 STAT3 抗炎活性介导的造血细胞保护反应
- 批准号:
9906160 - 财政年份:2018
- 资助金额:
$ 9.58万 - 项目类别:
Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity
定义 STAT3 抗炎活性介导的造血细胞保护反应
- 批准号:
10393508 - 财政年份:2018
- 资助金额:
$ 9.58万 - 项目类别:
Regulation and function of nonlymphoid organ CD103 dendritic cells
非淋巴器官CD103树突状细胞的调节和功能
- 批准号:
8832406 - 财政年份:2015
- 资助金额:
$ 9.58万 - 项目类别:
Pathways regulating plasmacytoid dendritic cells in Peyers Patches
派氏斑中浆细胞样树突状细胞的调节途径
- 批准号:
8233828 - 财政年份:2012
- 资助金额:
$ 9.58万 - 项目类别:
Pathways regulating plasmacytoid dendritic cells in Peyers Patches
派氏斑中浆细胞样树突状细胞的调节途径
- 批准号:
8432435 - 财政年份:2012
- 资助金额:
$ 9.58万 - 项目类别:
Cytokine Regulation of Dendritic Cell Development
树突状细胞发育的细胞因子调节
- 批准号:
7240401 - 财政年份:2007
- 资助金额:
$ 9.58万 - 项目类别:
Cytokine Regulation of Dendritic Cell Development
树突状细胞发育的细胞因子调节
- 批准号:
7497558 - 财政年份:2007
- 资助金额:
$ 9.58万 - 项目类别:
MOLECULAR MECHANISMS CYTOKINE RECEPTOR SIGNALING
细胞因子受体信号转导的分子机制
- 批准号:
6173091 - 财政年份:1998
- 资助金额:
$ 9.58万 - 项目类别:
相似海外基金
Fatty Acid Metabolic Regulation of Anti-Tumor Immunity Against Irradiated Glioblastoma
脂肪酸代谢调节抗辐射胶质母细胞瘤的免疫
- 批准号:
10638744 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven Cancer
SHOC2 全磷酸酶复合物在 RAS 驱动的癌症中的结构和功能
- 批准号:
10662750 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
用于治疗侵袭性癌症的双重作用免疫刺激纳米颗粒
- 批准号:
10618487 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Characterization of the Regulation and Gene Targets of TBX2 in Rhabdomyosarcoma
横纹肌肉瘤中 TBX2 的调控和基因靶点的表征
- 批准号:
10731025 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer
靶向巨噬细胞中的 KLF2 以改善肝细胞癌的免疫检查点治疗
- 批准号:
10677187 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Harnessing the repetitive genome for cancer immunotherapy
利用重复基因组进行癌症免疫治疗
- 批准号:
10664127 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Role of ADAR1 and dsRNA in age-related neuroinflammation and Alzheimers disease
ADAR1 和 dsRNA 在年龄相关神经炎症和阿尔茨海默病中的作用
- 批准号:
10752386 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
The Oncogene Activated Mitochondrial Unfolded Protein Response Regulates Senescence Biology
癌基因激活线粒体未折叠蛋白反应调节衰老生物学
- 批准号:
10598922 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别:
Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy
滤泡调节性 T 细胞作为癌症免疫治疗新细胞靶点的评估
- 批准号:
10737557 - 财政年份:2023
- 资助金额:
$ 9.58万 - 项目类别: